Pathway enrichment and clustering with REVIGO for the overlapping gene sets (35) (Fig 6C and Table S12) identifies pathways involved in the cell cycle, WNT signalling, NFKB signalling, and the cytoskeleton as being altered in response to application of either drug, confirming that application of these inhibitors impacts cancer cell phenotype through our proposed mechanisms. Here, NFKB1 is linked to cancer.